Heartland Advisors Inc. Takes Position in Envista Holdings Co. (NYSE:NVST)

Heartland Advisors Inc. purchased a new stake in Envista Holdings Co. (NYSE:NVST) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 214,777 shares of the company’s stock, valued at approximately $4,143,000. Heartland Advisors Inc. owned 0.12% of Envista as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Venturi Wealth Management LLC increased its position in shares of Envista by 528.4% in the fourth quarter. Venturi Wealth Management LLC now owns 1,948 shares of the company’s stock worth $38,000 after acquiring an additional 1,638 shares in the last quarter. GAMMA Investing LLC grew its position in Envista by 30.5% during the 4th quarter. GAMMA Investing LLC now owns 2,304 shares of the company’s stock worth $44,000 after purchasing an additional 538 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Envista during the 4th quarter valued at $53,000. Mitsubishi UFJ Trust & Banking Corp purchased a new stake in shares of Envista in the fourth quarter valued at $86,000. Finally, KBC Group NV boosted its position in shares of Envista by 63.9% in the fourth quarter. KBC Group NV now owns 7,903 shares of the company’s stock worth $152,000 after buying an additional 3,082 shares during the period.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on NVST. New Street Research set a $19.00 target price on Envista in a report on Thursday, March 6th. Morgan Stanley decreased their price target on Envista from $20.00 to $19.00 and set an “equal weight” rating for the company in a research note on Thursday, March 6th. Wells Fargo & Company set a $19.00 target price on shares of Envista in a report on Saturday, March 8th. Piper Sandler increased their price objective on Envista from $17.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday, February 3rd. Finally, JPMorgan Chase & Co. decreased their target price on Envista from $20.00 to $19.00 and set a “neutral” rating on the stock in a research report on Thursday, March 6th. Two analysts have rated the stock with a sell rating, ten have given a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $20.18.

Envista Stock Performance

Shares of NYSE:NVST opened at $16.96 on Friday. Envista Holdings Co. has a twelve month low of $15.15 and a twelve month high of $23.00. The business has a fifty day moving average of $19.59 and a 200-day moving average of $19.58. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.76 and a current ratio of 2.04. The firm has a market cap of $2.92 billion, a PE ratio of -2.61, a price-to-earnings-growth ratio of 1.27 and a beta of 1.33.

Envista (NYSE:NVST) last released its earnings results on Wednesday, February 5th. The company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. On average, equities research analysts predict that Envista Holdings Co. will post 1 EPS for the current fiscal year.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.